We are live on ! Find out more
BBC icon

Virtus Biotech Clinical Trials ETF
BBC

15 hedge funds and large institutions have $4.78M invested in Virtus Biotech Clinical Trials ETF in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.66% less ownership

Funds ownership: 34.29% → 31.63% (-2.7%)

17% less funds holding

Funds holding: 18 → 15 (-3)

33% less capital invested

Capital invested by funds: $7.19M → $4.78M (-$2.41M)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
15
Holders Change
-3
Holders Change %
-16.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
+$149K
2
Morgan Stanley
Morgan Stanley
New York
+$5.52K

Top Sellers

Rank Fund Capital Flow
1
FTUS
Flow Traders U.S.
New York
-$530K
2
LPL Financial
LPL Financial
California
-$344K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$152K
4
UBS Group
UBS Group
Switzerland
-$29.8K
5
MCC
Money Concepts Capital
Florida
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$2.16M – – –
Royal Bank of Canada
2
Royal Bank of Canada
Ontario, Canada
$1.69M -$152K -6,908 -8%
LPL Financial
3
LPL Financial
California
$481K -$344K -15,640 -41%
Osaic Holdings
4
Osaic Holdings
Arizona
$202K +$149K +6,800 +267%
Morgan Stanley
5
Morgan Stanley
New York
$151K +$5.52K +251 +4%
US Bancorp
6
US Bancorp
Minnesota
$22K – – –
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Quebec, Canada
$18.1K – – –
HI
8
Harbour Investments
Wisconsin
$18K +$18K +819 New
CAPTRUST Financial Advisors
9
CAPTRUST Financial Advisors
North Carolina
$14K – – –
GRP
10
Global Retirement Partners
California
$9K – – –
UBS Group
11
UBS Group
Switzerland
$7K -$29.8K -1,355 -80%
MW
12
Milestone Wealth
New York
$5K -$4.75K -216 -50%
ARMC
13
American Research & Management Company
Massachusetts
$2K – – –
FTUS
14
Flow Traders U.S.
New York
– -$530K -18,961 Closed
Wells Fargo
15
Wells Fargo
California
– -$6K -225 Closed
MCC
16
Money Concepts Capital
Florida
– -$6K -220 Closed
ODG
17
O'Dell Group
Ohio
– -$3K -117 Closed

BBC Hedge Fund Activity: Q2 2022 in Review

15 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q2 2022, worth a combined $4.78M — down 33% from $7.19M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BBC and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Osaic Holdings, adding an estimated $149K. The largest seller was Flow Traders U.S., exiting entirely with an estimated $530K sold.

  • 15 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q2 2022, down from 18 in Q1 2022.
  • Funds reported $4.78M of Virtus Biotech Clinical Trials ETF stock for Q2 2022, down 33% quarter-over-quarter.
  • 1 fund opened new Virtus Biotech Clinical Trials ETF positions in Q2 2022 and 4 closed out, a net change of -3 holders.
  • The largest Virtus Biotech Clinical Trials ETF buyer in Q2 2022 was Osaic Holdings, an estimated $149K added.
  • The largest Virtus Biotech Clinical Trials ETF seller in Q2 2022 was Flow Traders U.S., an estimated $530K sold.

Based on aggregated 13F filings for Q2 2022.